Quagen Pharma India Profile
Key Indicators
- Authorised Capital ₹ 45.00 Cr
as on 12-07-2024
- Paid Up Capital ₹ 32.44 Cr
as on 12-07-2024
- Company Age 9 Year, 9 Months
- Last Filing with ROC 31 Mar 2018
- Revenue 5.86%
(FY 2018)
- Profit 86.47%
(FY 2018)
- Ebitda 77.48%
(FY 2018)
- Net Worth -0.08%
(FY 2018)
- Total Assets 11.73%
(FY 2018)
About Quagen Pharma India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 45.00 Cr and a paid-up capital of Rs 32.44 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Quagen Pharma India Private Limited India is Rimpy Choudhury as COMPANY SECRETARY. Srikanth Dandamudi, Narsinh Desai, and Ashish Shah serve as directors at the Company.
- CIN/LLPIN
U74900AP2015FTC096297
- Company No.
096297
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
10 Mar 2015
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Quagen Pharma India?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rimpy Choudhury  | Company Secretary | 15-Dec-2019 | Current |
Ashish Shah  | Managing Director | 26-Mar-2015 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Srikanth Dandamudi | Director | 21-Apr-2015 | Current |
| Narsinh Desai | Director | 21-Apr-2015 | Current |
Financial Performance of Quagen Pharma India.
Quagen Pharma India Private Limited, for the financial year ended 2018, experienced modest growth in revenue, with a 5.86% increase. The company also saw a substantial improvement in profitability, with a 86.47% increase in profit. The company's net worth dipped by a decrease of 0.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Quagen Pharma India?
In 2018, Quagen Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sionc Pharmaceuticals Private LimitedActive 16 years 10 monthsSrikanth Dandamudi is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Quagen Pharma India?
Quagen Pharma India has a workforce of 4 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Quagen Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Quagen Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
